Piper Sandler downgraded Tourmaline Bio (TRML) to Neutral from Overweight with a price target of $48, down from $65, after the company agreed to be acquired by Novartis (NVS) for $1.4B in cash, or $48 per share.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRML:
- Tourmaline Bio downgraded to Neutral from Buy at H.C. Wainwright
- Tourmaline Bio downgraded to Hold from Buy at Truist
- Tourmaline Bio downgraded to Neutral from Buy at Chardan
- Tourmaline Bio downgraded to Hold from Buy at Jefferies
- Nebius enters AI pact with Microsoft, Teck to combine with Anglo: Morning Buzz